Background/Objectives: We assessed whether preprocedural serum albumin adds prognostic information to the PCI-derived Mehran score for early contrast-associated acute kidney injury (CA-AKI) after elective carotid artery stenting (CAS). Methods: This single-centre retrospective cohort included 121 consecutive elective patients (January 2020–April 2026). The primary model combined the reconstructed Mehran score with albumin < 3.5 g/dL, a conventional threshold fixed in advance. Because the score uses actual contrast volume, the combined model applies only after CAS. The outcome used KDIGO serum creatinine thresholds (≥0.3 mg/dL or ≥1.5 times baseline) from routine second-day testing. Internal validation used 1000 bootstrap resamples. Results: Early CA-AKI occurred in 32 patients (26.4%). Adjusted odds ratios were 1.35 per Mehran point (95% CI 1.13–1.60) and 11.68 for albumin < 3.5 g/dL (95% CI 4.14–32.97). AUC increased from 0.768 to 0.865 (95% CI 0.794–0.937; likelihood ratio χ2 = 24.58, p < 0.001). Corrected AUC, calibration slope, and Brier score were 0.860, 0.96, and 0.132. In exploratory decision curves (20% threshold), corrected net benefit was 0.168 for the combined model and 0.133 for Mehran alone. Conclusions: Low preprocedural albumin added prognostic information to the PCI-derived score and may help select patients for closer renal surveillance after CAS. External validation and prospective impact studies are needed before clinical use.
No takes yet. Share an insight, caveat, or question.
Karataş et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: